Trial Profile
A Phase I/II Study Testing the Safety, Toxicities, and Efficacy of MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Glioblastoma; Glioma
- Focus Adverse reactions; Therapeutic Use
- 04 Apr 2022 Planned End Date changed from 30 Nov 2023 to 30 Mar 2024.
- 04 Apr 2022 Planned primary completion date changed from 30 Nov 2023 to 30 Mar 2024.
- 12 Aug 2021 Planned number of patients changed from 58 to 55.